Intervju med vd Andreas Bhagwani 23 april 2025
23 April, 2025
Intervju med vd Andreas Bhagwani om delårsrapporten för första kvartalet, ny order och förbättringar i produktionen. Länk till intervjun
Latest news
Categories
News archive
Nanologica AB Receives Order Worth USD 180,000 from New Customer in China
23 April, 2025
Nanologica has received an order for the company’s silica-based purification media NLAB Saga® from a new customer in China. The customer is a large pharmaceutical manufacturer, and the order relates to evaluation of NLAB Saga® on a production scale. The order, which is worth USD 180,000, will be delivered during the second quarter. ”This is a highly interesting customer for us as it is larger than some of the others we work with. Among other
CEO COMMENT Q1 2025
16 April, 2025
SALES RECORD FOR A SINGLE QUARTER The first quarter of the year meant a sales record for a single quarter for the company and a good start to the new year. The ongoing positive customer dialogues combined with a continued stabilization of the production process create good conditions for increased sales growth during the year. Net sales for the quarter amounted to SEK 10,751 thousand and consist mainly of sales of our silica media NLAB
Interim Report Q1 2025
16 April, 2025
FINANCIAL SUMMARY Net sales for the first quarter amounted to SEK 10,751 thousand (5,037) The operating loss amounted to SEK 9,241 thousand (15,331) Loss after tax amounted to SEK 10,171 thousand (16,734) Earnings per share before and after dilution were SEK -0.12 (-0.46) Cash and cash equivalents per 31 March 2024 amounted to SEK 28,348 thousand (23,600). Shortly after the end of the quarter, the company’s cash and cash equivalents increased by approximately SEK 7
CEO Comment Annual Report 2024
28 March, 2025
After many years of working with various technologies and products, Nanologica has developed into a pure chromatography company with products for purification of pharmaceuticals during production, on a global market. Today we provide pharmaceutical manufacturers with products that needed to manufacture fast-growing GLP-1 analogues and insulin. With these products and our expertise in method and application development, we can streamline our customers’ workflows and reduce their costs. This makes us relevant in a market characterized
Annual Report 2024
28 March, 2025
The Annual Report for 2024 is now available Annual Report 2024 Nanologica AB (publ)